ONO Pharmaceutical Co Ltd (JP:4528)
:4528
Want to see JP:4528 full AI Analyst Report?
Top Page
ONO Pharmaceutical Co
(4528)
Select Model
Select Model
Rating:73Outperform
Price Target:
¥2,766.00
▲(21.72% Upside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by strong financial fundamentals—especially a conservative balance sheet and generally healthy cash generation—offset by less consistent profitability and cash-flow coverage in recent periods. Technicals are supportive from a trend (price above key moving averages) but are tempered by weak momentum (negative MACD). Valuation is reasonable, helped by a ~3.23% dividend yield and a mid-teens P/E.
Positive Factors
Conservative balance sheet
A low-leverage, equity-heavy balance sheet increases financial resilience and flexibility over time. It reduces refinancing and interest-rate risk, supports continued R&D investment and M&A optionality, and helps the company absorb cyclical dips without impairing core operations.
Negative Factors
Volatile profitability
Large swings in net profit indicate less predictable earnings power. Volatility can complicate reinvestment planning, make funding large clinical/met commercial initiatives harder to time, and raises execution risk for sustaining returns in coming periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
A low-leverage, equity-heavy balance sheet increases financial resilience and flexibility over time. It reduces refinancing and interest-rate risk, supports continued R&D investment and M&A optionality, and helps the company absorb cyclical dips without impairing core operations.
Read all positive factors
ONO Pharmaceutical Co (4528) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.13T
Dividend Yield3.63%
Average Volume (3M)2.41M
Price to Earnings (P/E)16.2
Beta (1Y)0.53
Revenue Growth5.94%
EPS Growth39.34%
CountryJP
Employees3,853
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)148.49
Shares Outstanding498,692,800
10 Day Avg. Volume2,786,750
30 Day Avg. Volume2,407,313
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.39
Price to Sales (P/S)2.29
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,900.00Price Target Upside-16.39% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)144.19
Revenue Forecast (FY)¥459.51B
ONO Pharmaceutical Co Business Overview & Revenue Model
Company Description
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous ...
How the Company Makes Money
ONO Pharmaceutical primarily makes money from (1) net sales of prescription pharmaceuticals it commercializes and (2) collaboration-related income such as royalties and milestone/other payments tied to partnered products. The largest revenue strea...
ONO Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 515.78B | 486.87B | 502.67B | 447.19B | 361.36B |
| Gross Profit | 374.07B | 335.47B | 372.67B | 334.28B | 264.91B |
| EBITDA | 141.09B | 90.28B | 181.70B | 169.75B | 132.63B |
| Net Income | 69.77B | 50.05B | 127.98B | 112.72B | 80.52B |
Balance Sheet | |||||
| Total Assets | 1.11T | 1.06T | 913.67B | 882.44B | 739.20B |
| Cash, Cash Equivalents and Short-Term Investments | 237.11B | 210.38B | 204.59B | 164.29B | 116.97B |
| Total Debt | 120.94B | 146.68B | 8.86B | 9.17B | 8.80B |
| Total Liabilities | 249.87B | 275.84B | 115.06B | 134.62B | 77.53B |
| Stockholders Equity | 850.73B | 782.45B | 792.96B | 741.87B | 655.91B |
Cash Flow | |||||
| Free Cash Flow | 130.80B | 77.03B | 106.64B | 154.27B | 56.33B |
| Operating Cash Flow | 136.82B | 82.46B | 110.66B | 159.61B | 61.83B |
| Investing Cash Flow | -39.86B | -136.78B | 48.08B | -100.26B | 6.04B |
| Financing Cash Flow | -65.49B | 94.30B | -89.85B | -32.48B | -60.24B |
ONO Pharmaceutical Co Technical Analysis
Negative
2272.50
Price Trends
2432.31
Negative
2392.33
Positive
2105.91
Positive
Market Momentum
-4.68
Positive
46.52
Neutral
28.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4528, the sentiment is Negative. The current price of 2272.5 is below the 20-day moving average (MA) of 2425.02, below the 50-day MA of 2432.31, and above the 200-day MA of 2105.91, indicating a neutral trend. The MACD of -4.68 indicates Positive momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 28.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4528.
ONO Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥1.13T | 16.15 | 6.03% | 3.63% | 5.94% | 39.34% | |
72 Outperform | ¥12.74T | 28.72 | 22.23% | 1.17% | 5.65% | 10.24% | |
69 Neutral | ¥1.29T | 17.99 | 4.27% | 2.33% | 3.20% | 43.05% | |
65 Neutral | ¥3.82T | 14.06 | 7.97% | 3.61% | 11.87% | 474.27% | |
65 Neutral | ¥1.10T | 29.13 | 5.75% | 3.51% | 4.56% | -16.55% | |
61 Neutral | ¥4.96T | 19.08 | 18.56% | 2.07% | 12.55% | -10.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4528
ONO Pharmaceutical Co
2,392.50
887.34
58.95%
JP:4503
Astellas Pharma
2,283.00
908.75
66.13%
JP:4519
Chugai Pharmaceutical Co
7,892.00
564.36
7.70%
JP:4568
Daiichi Sankyo Company
2,700.50
-1,046.19
-27.92%
JP:4523
Eisai Co
3,984.00
-26.33
-0.66%
JP:4151
Kyowa Kirin Co
2,505.00
208.98
9.10%
ONO Pharmaceutical Co Corporate Events
ONO Pharmaceutical Details FY2025 Results and FY2026 Outlook with Focus on Pipeline and Core Metrics
May 8, 2026
ONO Pharmaceutical Co., Ltd. released supplementary materials for its fiscal year 2025 consolidated financial results on a core basis, covering the period from April 1, 2025 to March 31, 2026. The materials outline sales revenue for major products...
Ono Pharmaceutical Delivers Strong FY 2025 Profits but Guides for Lower Revenue in FY 2026
May 8, 2026
Ono Pharmaceutical reported fiscal 2025 revenue of ¥515.8 billion, up 5.9% year on year, with operating profit surging 54.4% and profit attributable to owners jumping 39.4%, reflecting improved margins and stronger core earnings. The company ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.